Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide,for the prevention of migraine: a phase 2, randomised,double-blind,placebo-controlled study |
| |
| Authors: | David W Dodick Peter J Goadsby Egilius L H Spierings Joel C Scherer Steven P Sweeney David S Grayzel |
| |
| Affiliation: | 1. Department of Neurology, Mayo Clinic, Phoenix, AZ, USA;2. NIHR Wellcome Trust Clinical Research Facility, Kings College London, London, UK;3. Department of Neurology, University of California, San Francisco CA, USA;4. Department of Neurology, Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;5. Craniofacial Pain Center, Tufts University School of Dental Medicine, Boston, MA, USA;6. Headache and Face Pain Program, Tufts Medical Center, Boston, MA, USA;7. Eli Lilly and Company, Indianapolis, IN, USA;8. Arteaus Therapeutics, Cambridge, MA, USA |
| |
| Abstract: | ![]()
|
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
